



## Dolphin® used in Turkey for SRS and SBRT treatment Quality Assurance for safer Radiation Therapy

*Innovative Dolphin® system clinically implemented at the Gaziosmanpasa Hospital, Istanbul, ensuring high quality and efficient radiosurgery and SBRT treatment QA*

**Istanbul, March 21, 2017** – IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of proton therapy solutions and radiation therapy quality assurance for the treatment of cancer, announces the **first clinical implementation of Dolphin** Online Ready Patient QA and Monitoring solution in Turkey.

With the use of **Dolphin**, the team at the Gaziosmanpasa Hospital in Istanbul, Turkey, implemented a **new quality assurance standard for challenging radiosurgery and Stereotactic Body Radiation Therapy (SBRT) cases**. These patient treatments are delivered with high doses typically in five or less treatment fractions precisely tailored to the tumor's shape and location. To address the special high demands of SRS and SBRT cases the hospital's team has clinically implemented Dolphin due to the system's ability to verify treatment doses in 3D within the patient's individual anatomy.

*"We are now using Dolphin to perform patient QA for our advanced and challenging stereotactic cases and for our Head & Neck treatments"* says **Bora Tas, Asst. Prof. and Chief Medical Physicist at the Gaziosmanpasa Hospital in Istanbul, Turkey.**

He continues, *"compared to our previous table based QA solution we can now measure and verify our patient QA in significantly less time"*.



### About the Dolphin System

Dolphin is a complete solution that offers a **higher capability to detect and verify possible treatment dose discrepancies** compared to conventional QA solutions, thus contributing to a **more efficient and safer radiation therapy**. This improvement is based on Dolphin's high treatment dose measurement resolution.

Highly complex IMRT and rotational treatment plans are delivered and measured with the Dolphin transmission detector prior to each patient treatment. A sophisticated TPS-Class software allows

Press release | 21/03/2017

**IBA | Dosimetry GmbH**

Bahnhofstr. 5 | 90592 Schwarzenbruck | Germany | T +49 9128 607 0 | F +49 9128 607-10

Registration Court: Local Court (Amtsgericht) Nürnberg, HRB 4262

Managing Directors (Geschäftsführer): Olivier Legrain, Robby Plompen, Berthold Baldus

[Dosimetry-info@iba-group.com](mailto:Dosimetry-info@iba-group.com) | [www.iba-dosimetry.com](http://www.iba-dosimetry.com)

**PROTECT +  
ENHANCE +  
SAVE LIVES**



**verification of dose deviations in 3D patient anatomy** between the plan and actual delivered dose measured with Dolphin.

The hospital's **patient QA workflow efficiency** is increased with Dolphin's "plug and play" wireless setup and its automatic verification software displaying instant QA results.

The Dolphin solution including the detector and the software is "online ready" and currently used for pre-treatment QA. The system will be capable of **measuring the actual patient treatment dose in online mode, fraction by fraction**. The online capability is currently pending release.

For more information visit <http://www.iba-dosimetry.com/>

### About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)

### About Yeni Yuzyil University Gaziosmanpasa Hospital

Yeni Yuzyil University Gaziosmanpasa (GOP) Hospital opened in 1992 as a private international hospital in Istanbul with a bed capacity of 350. Today, the hospital has a reputation for outstanding service to its patients, which has been accomplished by ensuring uncompromised reliability and offering state of the art technology. The medical oncology and radiation oncology department opened in 2014. At the time of writing, 450 patients have been treated using SRS/ SRT/SBRT techniques, 2,500 patients with IMRT/VMAT techniques, and 350 patients with 3D conformal techniques by two Elekta Versa HD linear accelerators. The radiation oncology department treats approximately 1,400 patients per year, with an experienced staff comprised of: two Radiation Oncologists, two Medical Physicists, one Dosimetrist, and seven Therapists.

### Contact:

Ralf Schira  
Vice President Marketing  
IBA Dosimetry  
ralf.schira@iba-dosimetry.com  
<http://www.iba-dosimetry.com/>

Press release | 21/03/2017

IBA | Dosimetry GmbH

Bahnhofstr. 5 | 90592 Schwarzenbruck | Germany | T +49 9128 607 0 | F +49 9128 607-10

Registration Court: Local Court (Amtsgericht) Nürnberg, HRB 4262

Managing Directors (Geschäftsführer): Olivier Legrain, Robby Plompen, Berthold Baldus

[Dosimetry-info@iba-group.com](mailto:Dosimetry-info@iba-group.com) | [www.iba-dosimetry.com](http://www.iba-dosimetry.com)

PROTECT +  
ENHANCE +  
SAVE LIVES